Antitumor activity of 7-aminocarboxycoumarin derivatives, a new class of potent inhibitors of lactate influx but not efflux

Molecular Cancer Therapeutics

Volumn 13, Issue 6, 2014, Pages 1410-1418

  Draoui, Nihed ^a   Schicke, Olivier ^a   Seront, Emmanuel ^a   Bouzin, Caroline ^a   Sonveaux, Pierre ^a   Riant, Olivier ^a   Feron, Olivier ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

7 AMINOCARBOXYCOUMARIN DERIVATIVE; ANTINEOPLASTIC AGENT; AR C 155858; BROMOPYRUVIC ACID; CISPLATIN; COUMARIN DERIVATIVE; LACTIC ACID; MONOCARBOXYLATE TRANSPORTER; MONOCARBOXYLATE TRANSPORTER 1; MONOCARBOXYLATE TRANSPORTER 4; PYRUVIC ACID; UNCLASSIFIED DRUG; AR C155858; COUMARIN; THIOPHENE DERIVATIVE; URACIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CANCER PROGNOSIS; CANCER RECURRENCE; CITRIC ACID CYCLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; FEMALE; GLYCOLYSIS; HCT116 CELL LINE; HUMAN; HUMAN CELL; MCF 7 CELL LINE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; BREAST NEOPLASMS; CHEMISTRY; COLORECTAL NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS;

ANIMALS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; COUMARINS; FEMALE; HCT116 CELLS; HUMANS; LACTIC ACID; MCF-7 CELLS; MICE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; THIOPHENES; URACIL;

EID: 84902658757     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0653     Document Type: Article

References (46)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
2. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 2011;11:85-95.
3. Warburg O. On the origin of cancer cells. Science 1956;123:309-14.
4. Scatena R. Mitochondria and cancer: a growing role in apoptosis, cancer cell metabolism and dedifferentiation. Adv Exp Med Biol 2012;942:287-308.
5. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 2011;11:325-37.
6. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012;21:297-308.
7. Daye D, Wellen KE. Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis. Semin Cell Dev Biol 2012;23:362-9.
8. Feron O. Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiother Oncol 2009;92:329-33.
9. Dhup S, Dadhich RK, Porporato PE, Sonveaux P. Multiple biological activities of lactic acid in cancer: influences on tumor growth, angiogenesis and metastasis. Curr Pharm Des 2012;18:1319-30.
10. Polet F, Feron O. Endothelial cell metabolism and tumour angiogenesis: glucose and glutamine as essential fuels and lactate as the driving force. J Intern Med 2013;273:156-65.
11. Sonveaux P, Vegran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 2008;118:3930-42.
12. Boidot R, Vegran F, Meulle A, Le BA, Dessy C, Sonveaux P, et al. Regulation of monocarboxylate transporter MCT1 expression by p53 mediates inward and outward lactate fluxes in tumors. Cancer Res 2012;72:939-48.
13. Fiaschi T, Marini A, Giannoni E, Taddei ML, Gandellini P, De DA, et al. Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay. Cancer Res 2012;72:5130-40.
14. Whitaker-Menezes D, Martinez-Outschoorn UE, Lin Z, Ertel A, Flomenberg N, Witkiewicz AK, et al. Evidence for a stromal-epithelial "lactate shuttle" in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts. Cell Cycle 2011;10:1772-83.
15. Vegran F, Boidot R, Michiels C, Sonveaux P, Feron O. Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-kappaB/IL-8 pathway that drives tumor angiogenesis. Cancer Res 2011;71:2550-60.
16. Sonveaux P, Copetti T, De Saedeleer CJ, Vegran F, Verrax J, Kennedy KM, et al. Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis. PLoS ONE 2012;7:e33418.
17. De Saedeleer CJ, Copetti T, Porporato PE, Verrax J, Feron O, Sonveaux P. Lactate activates HIF-1 in oxidative but not in Warburg-phenotype human tumor cells. PLoS ONE 2012;7:e46571.
18. Walenta S, Salameh A, Lyng H, Evensen JF, Mitze M, Rofstad EK, et al. Correlation of high lactate levels in head and neck tumors with incidence of metastasis. Am J Pathol 1997;150:409-15. (Pubitemid 27073770)
19. Brizel DM, Schroeder T, Scher RL, Walenta S, Clough RW, Dewhirst MW, et al. Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;51:349-53. (Pubitemid 32884281)
20. Walenta S, Schroeder T, Mueller-Klieser W. Lactate in solid malignant tumors: potential basis of a metabolic classification in clinical oncology. Curr Med Chem 2004;11:2195-204. (Pubitemid 38967739)
21. Hirschhaeuser F, Sattler UG, Mueller-Klieser W. Lactate: a metabolic key player in cancer. Cancer Res 2011;71:6921-5.
22. Kennedy KM, Dewhirst MW. Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation. Future Oncol 2010;6:127-48.
23. Draoui N, Feron O. Lactate shuttles at a glance: from physiological paradigms to anti-cancer treatments. Dis Model Mech 2011;4:727-32.
24. Halestrap AP. The SLC16 gene family - structure, role and regulation in health and disease. Mol Aspects Med 2013;34:337-49.
25. Pinheiro C, Longatto-Filho A, Azevedo-Silva J, Casal M, Schmitt FC, Baltazar F. Role of monocarboxylate transporters in human cancers: state of the art. J Bioenerg Biomembr 2012;44:127-39.
26. Ullah MS, Davies AJ, Halestrap AP. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J Biol Chem 2006;281:9030-7. (Pubitemid 43864615)
27. Jackson VN, Halestrap AP. The kinetics, substrate, and inhibitor specifi city of the monocarboxylate (lactate) transporter of rat liver cells determined using the fl uorescent intracellular pH indicator, 2′,7′- bis(carboxyethyl)-5(6)-carboxy fluorescein. J Biol Chem 1996;271:861-8.
28. Dimmer KS, Friedrich B, Lang F, Deitmer JW, Broer S. The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells. Biochem J 2000;350 Pt 1:219-27.
29. Poole RC, Cranmer SL, Halestrap AP, Levi AJ. Substrate and inhibitor specificity of monocarboxylate transport into heart cells and erythrocytes. Further evidence for the existence of two distinct carriers. Biochem J 1990;269:827-9. (Pubitemid 20236098)
30. Halestrap AP, Poole RC, Cranmer SL. Mechanisms and regulation of lactate, pyruvate and ketone body transport across the plasma membrane ofmammalian cells and their metabolic consequences. Biochem Soc Trans 1990;18:1132-5.
31. Wilson MC, Meredith D, Fox JE, Manoharan C, Davies AJ, Halestrap AP. Basigin (CD147) is the target for organomercurial inhibition of monocarboxylate transporter isoforms 1 and 4: the ancillary protein for the insensitive MCT2 is EMBIGIN (gp70). J Biol Chem 2005;280:27213- 21.
32. Poole RC, Halestrap AP. Inhibition and labelling of the erythrocyte lactate transporter by stilbene disulphonates. Biochem Soc Trans 1990;18:1245-6.
33. Wilson MC, Meredith D, Bunnun C, Sessions RB, Halestrap AP. Studies on the DIDS-binding site of monocarboxylate transporter 1 suggest a homology model of the open conformation and a plausible translocation cycle. J Biol Chem 2009;284:20011-21.
34. Halestrap AP, Denton RM. The specificity and metabolic implications of the inhibition of pyruvate transport in isolated mitochondria and intact tissue preparations by alpha-Cyano-4-hydroxycinnamate and related compounds. Biochem J 1975;148:97-106.
35. Halestrap AP. The mitochondrial pyruvate carrier. Kinetics and specificity for substrates and inhibitors. Biochem J 1975;148:85-96.
36. Ovens MJ, Davies AJ, Wilson MC, Murray CM, Halestrap AP. ARC155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7-10. Biochem J 2010;425:523-30.
37. Ovens MJ, Manoharan C, Wilson MC, Murray CM, Halestrap AP. The inhibition of monocarboxylate transporter 2 (MCT2) by AR-C155858 is modulated by the associated ancillary protein. Biochem J 2010;431:217-25.
38. Draoui N, Schicke O, Fernandes A, Drozak X, Nahra F, Dumont A, et al. Synthesis and pharmacological evaluation of carboxycoumarins as a new antitumor treatment targeting lactate transport in cancer cells. Bioorg Med Chem 2013;21:7107-17.
39. Pedersen PL. 3-Bromopyruvate (3BP) a fast acting, promising, powerful, specific, and effective "small molecule" anti-cancer agent taken from labside to bedside: introduction to a special issue. J Bioenerg Biomembr 2012;44:1-6.
40. Birsoy K, Wang T, Possemato R, Yilmaz OH, Koch CE, Chen WW, et al. MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors. Nat Genet 2013;45:104-8.
41. Seront E, Boidot R, Bouzin C, Karroum O, Jordan BF, Gallez B, et al. Tumour hypoxia determines the potential of combining mTOR and autophagy inhibitors to treat mammary tumours. Br J Cancer 2013;109:2597-606.
42. Altman BJ, Dang CV. Normal and cancer cell metabolism: lymphocytes and lymphoma. FEBS J 2012;279:2598-609.
43. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene 2012;31:1869-83.
44. Rothman RB, Dersch CM, Ananthan S, Partilla JS. Studies of the biogenic amine transporters. 13. Identification of "agonist" and "antagonist" allosteric modulators of amphetamine-induced dopamine release. J Pharmacol Exp Ther 2009;329:718-28.
45. Bueno V, Binet I, Steger U, Bundick R, Ferguson D, Murray C, et al. The specific monocarboxylate transporter (MCT1) inhibitor, AR-C117977, a novel immunosuppressant, prolongs allograft survival in the mouse. Transplantation 2007;84:1204-7. (Pubitemid 350125365)
46. Curry JM, Tuluc M, Whitaker-Menezes D, Ames JA, Anantharaman A, Butera A, et al. Cancer metabolism, stemness and tumor recurrence: MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer. Cell Cycle 2013;12:1371-84.